Ocular Therapeutix Inc. (NASDAQ:OCUL)’s share price dropped 4.8% during trading on Monday . The company traded as low as $6.05 and last traded at $6.16, with a volume of 1,814,720 shares traded. The stock had previously closed at $6.47.

Several equities analysts recently issued reports on the stock. BTIG Research reissued a “buy” rating and set a $18.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, July 26th. Morgan Stanley reissued an “overweight” rating and set a $16.00 price objective (down from $17.00) on shares of Ocular Therapeutix in a report on Tuesday, June 7th. Zacks Investment Research lowered shares of Ocular Therapeutix from a “buy” rating to a “hold” rating in a report on Wednesday, May 11th. Cowen and Company reissued a “buy” rating on shares of Ocular Therapeutix in a report on Monday, June 6th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $48.00 price objective on shares of Ocular Therapeutix in a report on Sunday, April 10th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Ocular Therapeutix has an average rating of “Buy” and a consensus target price of $22.81.

The stock has a 50-day moving average of $5.06 and a 200-day moving average of $8.21. The stock’s market cap is $151.32 million.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.01. The firm had revenue of $458 million for the quarter. On average, equities research analysts anticipate that Ocular Therapeutix Inc. will post ($1.86) EPS for the current fiscal year.

In related news, CEO Amarpreet Sawhney acquired 10,000 shares of the firm’s stock in a transaction dated Thursday, June 9th. The shares were purchased at an average cost of $6.70 per share, for a total transaction of $67,000.00. Following the acquisition, the chief executive officer now owns 573,733 shares in the company, valued at approximately $3,844,011.10. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.